The Immunology of Composite Tissue Transplantation

Clinics in Plastic Surgery

Volumn 34, Issue 2, 2007, Pages 303-317

  Pidwell, Diane J ^a   Burns, Carolyn ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS;

ACNE; ALLOTRANSPLANTATION; BONE MARROW SUPPRESSION; COMPOSITE GRAFT; DIABETOGENESIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT REJECTION; GROWTH RETARDATION; HIRSUTISM; HISTOCOMPATIBILITY TEST; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY FAILURE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; SIDE EFFECT;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TISSUE TRANSPLANTATION;

EID: 34047099687     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2006.12.002     Document Type: Review

References (86)

1. Merrill J.P., Murray J.E., Harrison J.H., et al. Successful homotransplantations of the human kidney between identical twins. JAMA 160 (1956) 277-282
2. In: Terasaki P. (Ed). Clinical transplants (1989), UCLA tissue typing laboratory, Los Angeles (CA) 19-20
3. Ekka-Zohar A., Zitser-Gurevich Y., Mandel M., et al. Graft survival and its determinants: a 3-year national experience with liver transplantation in Israel. Isr Med Assoc J 8 (2006) 400-405
4. Gjertson D.W. Explainable variation in renal transplant outcomes: a comparison of standard and expanded criteria donors. In: Ceck J.M., and Terasaki P.I. (Eds). Clinical Transplants 2004 (2004), UCLA Immunogenetics Center, Los Angeles 303-314
5. Mahle W.T., Kanter K.R., and Vincent R.N. Disparities in outcome for black patients after pediatric heart transplantation. J Pediatr 147 (2005) 739-743
6. Al-Khaldi A., Oyer P.E., and Robbins R.C. Outcome analysis of donor gender in heart transplantation. J Heart Lung transplant 25 (2006) 461-468
7. Adams P., Oprencak E., and Orosz C.G. LDA of human tetanus reactive helper T lymphocytes: a rapid method for enumeration of helper lymphocytes with specificity for soluble antigen. J Immunol Methods 142 (1991) 231-241
8. Orosz C.G., Adams P., and Ferguson R. Frequency of human alloantigen reactive T lymphocytes: II method for LDA for alloantigen reactive helper T cells in human peripheral blood. Transplantation 43 5 (1987) 718-724
9. Rogers N.J., and Lechler R.I. Allorecognition. Am J Transplant 1 (2001) 97-102
10. Liu X., Sun Y.K., Xi Y.P., et al. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 177 (1993) 1643-1650
11. Hornick P., and Lechler R. Direct and indirect pathways of alloantigen recognition: relevance to acute and chronic allograft rejection. Nephrol Dial Transplant 12 (1997) 1806-1810
12. Feucht H.E. Complement C4d in graft capillaries-the missing link in the recognition of humoral alloreactivity. Am J Transplant 3 6 (2003) 646-652
13. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713-723
14. Billingham M.E., Cary N.R.B., Hammond E.H., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant 9 (1990) 587-593
15. Kissmeyer-Nielsen F., Olsen S., Petersen V.P., et al. Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancet 2 (1966) 662-665
16. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 14 (1969) 735-739
17. Sumitran-Karuppan S., Tyden G., Reinholt F., et al. Hyperacute rejection of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 5 4 (1997) 321-327
18. Rifle G., Mousson C., Martin L., et al. Donor specific antibodies in allograft rejection: clinical and experimental data. Transplantation 79 3 Suppl (2005) S14-S18
19. Fishbein M.C., and Kobashigawa J. Biopsy negative cardiac transplant rejection: etiology, diagnosis and therapy. Curr Opin Cardiol 19 2 (2004) 166-169
20. Reed E.F., Demetris A.J., Hammond E., et al., for the International Society for Heart and Lung Transplantation. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 25 2 (2006) 153-159
21. Takemoto S.K., Zeevi A., Feng S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4 (2004) 1033-1041
22. Abraham K.A., Brown C., Conlon P.J., et al. Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J Clin Apher 18 3 (2003) 103-110
23. Rocha P.N., Butterfly D.W., Greenberg A., et al. Beneficial effects of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75 9 (2003) 1490-1495
24. Jordan S.C., Vo A.A., Toyoda M., et al. Post-transplant therapy with high-dose intraveneous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr Transplant 9 (2005) 155-161
25. Pelleitier M., and Montplaisir S. The nude mouse: a model of deficient T-cell function. Methods Achiev Exp Pathol 7 (1975) 149-166
26. Stoica S.C., Cafferty F., Math M., et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 25 (2006) 420-425
27. Baboolal K., Jones G.A., Janezic A., et al. Molecular and structural consequences of early renal allograft injury. Kidney Int 61 (2003) 686-696
28. Ramzy D., Rao J., Brahm J., et al. Cardiac allograft vasculopathy: a review. Can J Surg 48 4 (2005) 319-327
29. Nankwell B.J., Borrows R.J., Fung C., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 24 (2003) 2326-2333
30. Russell P.S., Chase C.M., Winn H.J., et al. Coronary atherosclerosis in transplanted mouse hearts: II importance of humoral immunity. J Immunol 152 10 (1994) 5135-5141
31. Csencsits K., Wood S.C., Lu G., et al. Transforming growth factor beta-induced connective tissue growth factor and chronic allograft rejection. Am J Transplant 6 5 pt 1 (2006) 959-966
32. Zdichavsky M., Jones J., Ustener T.E., et al. Scoring of skin rejection in a swine composite tissue allograft model. J Surg Res 85 (1999) 1-8
33. Daniel R.K., Egerszegi E.P., Samulack D.D., et al. Tissue transplants in primates for upper extremity reconstruction: a preliminary report. J hand Surg 11A 1 (1986) 1-8
34. Stark G.B., Swartz W.M., Narayanan K., et al. Hand transplantation in baboons. Transplant Proc 19 5 (1987) 3968-3971
35. Shirbacheh M.V., Jones J.W., Breidenbach W.C., et al. The case for local immunosuppression in composite tissue allotransplantation. Transplant Proc 30 6 (1998) 2739-2742
36. Gruber S.A., Shirbacheh M.V., Jones J.W., et al. Local drug delivery to composite tissue allografts. Microsurgery 20 8 (2000) 407-411
37. Ustuner E.T., Hajzoub R.K., Ren X., et al. Swine composite tissue allotransplant model for pre-clinical hand transplant studies. Microsurgery 20 8 (2000) 400-406
38. Smith D.M., Agura E., Netto G., et al. Liver transplant associated graft-versus-host disease. Transplantation 75 1 (2003) 118-126
39. Taylor A.L., Gibbs P., and Bradley J.A. Acute graft-versus-host disease following liver transplantation: the enemy within. Am J Transplant 4 (2004) 466-474
40. Mazariegos G.V., Abu-Elmagd K., Jaffe R., et al. Graft-versus-host disease in intestinal transplantation. Am J Transplant 4 (2004) 1459-1465
41. Sage D., Stanworth S., Turner D., et al. Diagnosis of transfusion-associated graft-versus-host disease: the importance of short tandem repeat analysis. Transfus Med 15 6 (2005) 481-485
42. Gorantla J.S., Prabhune K.A., Perez-Abadia G., et al. Composite tissue allotransplantation in chimeric hosts: part I. Prevention of graft-versus-host disease. Transplantation 75 7 (2003) 922-932
43. Brouha P., Perez-Abadia G., Francois C.G., et al. Lymphadenectomy in prior to rat hind limb allotransplantation prevents graft-versus-host disease in chimeric hosts. Transpl Int 17 7 (2004) 341-350
44. Ziring D., Tran R., Edelstein S., et al. Infectious enteritis after intestinal transplantation: incidence, timing and outcome. Transplantation 79 6 (2005) 702-709
45. Guaraldi B., Cocchi S., DeRuvo N., et al. Outcome, incidence, and timing of infections in small bowel/multivisceral transplantation. Transplant Proc 36 (2004) 383-385
46. Alexander B.D., and Tapson V.F. Infectious complications of lung transplantation. Transpl Infect Dis 3 (2001) 128-137
47. Sole A., Morant P., Salavert M., et al., the Valencia lung transplant group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11 5 (2005) 359-365
48. Ruttman E., Geltner C., Bucher B., et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81 10 (2006) 1415-1420
49. Opelz G., Wujciak T., Dohler B., et al. HLA compatibility and organ transplant survival. Collaborative transplant study. Rev Immunogenet 1 3 (1999) L334-L342
50. Opelz G., and for the Collaborative Transplant Study. New immunosuppressants and HLA matching. Transplant Proc 33 (2001) 467-468
51. Pescovitz M.D. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection. Clin Transpl 20 1 (2006) 48-54
52. Taylor A.L., Watson C.J.E., and Bradley A.J. Imunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 56 1 (2005) 23-46
53. Gorantla V.S., Barker J.H., Jones J.W., et al. Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies. Microsurgery 20 8 (2000) 420-429
54. Duncan M.D., and Wilkes D.S. Transplant-related immunosuppression. A review of immunosuppression and pulmonary infections. Proc Am Thorac Soc 2 (2005) 449-455
55. Offerman G. Immunosuppression for long term maintenance of renal allograft function. Drugs 64 12 (2004) 1325-1338
56. O'Neill J.O., Taylor D.O., and Starling R.C. Immunosuppression for cardiac transplantation-the past, present and future. Transplant Proc 36 Suppl 2S (2004) 309S-313S
57. Larsen C.P., Knechtle S.J., Adams A., et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 6 (2006) 876-883
58. Solomom B., and Bluestone J.A. Complexities of CD28/C7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19 (2001) 225-252
59. Watson C.J.E., Bradley J.A., Friend P.J., et al. Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 5 (2005) 1347-1353
60. Tonshoff B., Hocker B., and Weber L.T. Steroid withdrawal in pediatric and adult renal transplant recipients. Pediatr Nephrol 20 3 (2005) 409-417
61. Matos A.J., Kandaswamy R., Gillingham K.J., et al. Prednisone-free maintenance immunosuppression-a five year experience. Am J Transplant 5 (2005) 2473-2478
62. Gaston R.S., and Benfield M. The relationship between ethnicity and outcomes in solid organ transplantation. [editorial]. J Pediatr 147 (2005) 721-723
63. Gaston R.S. Cytokines and transplantation: a clinical perspective. Transplant Sci 4 Suppl 1 (1994) S9-S19
64. Bumgardner G., and Orosz C.G. Transplantation and cytokines. Semin Liver Dis 19 2 (1999) 189-204
65. Mosmann T.R., Cherwinsky H., Bond M.W., et al. Two types of murine helper T cell clones: I definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136 7 (1986) 2348-2357
66. Mosmann T.R., and Sad S. The expanding universe of T cell subsets: Th1, Th2 and more. Immunol Today 17 3 (1996) 138-146
67. Street N.E., and Mosmann T.R. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 5 (1991) 171-177
68. Chapman T.M., and Keating G.M. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 63 24 (2003) 2803-2835
69. VanGelder T., Warle M., and ter Meulen R.G. Anti-interleukin 2 receptor antibodies in transplantation. What is the basis for choice?. Drugs 64 16 (2004) 1737-1741
70. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens. Biodrugs 19 1 (2005) 39-46
71. Calne R., Moffatt S.D., Friend P.J., et al. Campath 1H allows low dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68 10 (1999) 1613-1616
72. Vathsala A., Ona E.T., Tan S.Y., et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplant. Transplantation 80 6 (2005) 765-774
73. Opelz G., Naujokat C., Daniel V., et al. Dissociation between risk of graft loss and risk of non-Hodgkins lymphoma with induction agents in renal transplant recipients. Transplantation 81 9 (2006) 1227-1233
74. Taylor A.L., Marcus R., and Bradley J.A. Post-transplant lympho-proliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56 (2005) 155-167
75. Sidner R.A., Book B.K., Agarwal A., et al. In vivo human B cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Human Antibody 13 (2004) 55-62
76. Viera C.A., Agarwal A., Book B.K., et al. Rituximab for reduction of anti-HLA antibody in patients awaiting renal transplantation: I safety, pharmacodynamics and pharmacokinetics. Transplantation 77 4 (2004) 542-548
77. Smith J.M., and McDonald R.A. Renal transplantation in adolescents. Adolesc Med Clin 16 1 (2005) 201-214
78. VanBuskirk A.M., Burlingham W.J., Jankowska-Gan E., et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 106 1 (2000) 145-155
79. Knechtle S.J., and Burlingham W.J. Metastable tolerance in non-human primates and humans. Transplantation 77 6 (2004) 936-939
80. Billingham R.E., Brent L., and Medawar P.B. Actively acquired tolerance of foreign cells. Nature 172 (1953) 603-606
81. Monaco A.P. The beginning of clinical tolerance in solid organ allografts. Exp Clinic Transplant 2 (2004) 153-161
82. Fehr T., and Sykes M. Tolerance induction in clinical transplantation. Transpl Immunol 33 (2004) 118-130
83. Brouha P.C.R., and Ildstad S.T. Mixed allogeneic chimerism past, present and prospects for the future. Transplantation 72 8 Suppl (2001) 536-542
84. Starzl T.E., Demetris A.J., Murase N., et al. Cell migration, chimerism, and graft acceptance. Lancet 339 (1992) 1579-1582
85. Light J., Salomon D.R., Diethelm A.G., et al. Bone marrow transfusion in cadaver renal allografts: pilot trials with concurrent controls. Clin Transpl 16 5 (2002) 317-324
86. Fields R.C., Bharat A., and Mohanakumar T. The role of regulatory T-cells in transplantation tolerance. ASHI Quarterly 30 1 (2006) 10-15